CRAFITY score benefits hepatocellular carcinoma patients treated with transarterial chemoembolization and lenvatinib

Abstract Background The CRAFITY score serves as a simple and effective predictive model for individuals diagnosed with hepatocellular carcinoma (HCC) and subjected to treatment with atezolizumab and bevacizumab (Atez/Bev). However, no large sample size studies have reported the application of the CR...

Description complète

Détails bibliographiques

Auteurs principaux:	Lin Zhang, Hongcai Yang, Shangkun Ning, Zhijuan Wu, Dianzhe Wang, Hexin Liang, Chunni Wang, Xu Chang
Format:	Artigo
Langue:	Inglês
Publié:	Wiley 2024-06-01
Collection:	Cancer Medicine
Sujets:	alpha‐fetoprotein CRAFITY score C‐reactive protein hepatocellular carcinoma Lenvatinib TACE
Accès en ligne:	https://doi.org/10.1002/cam4.7410
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!